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Abstract
Retinoic acid receptors (RARs) and Retinoid X nuclear receptors (RXRs) are ligand-dependent transcriptional modulators that
execute their biological action through the generation of functional heterodimers. RXR acts as an obligate dimer partner in
many signalling pathways, gene regulation by rexinoids depending on the liganded state of the specific heterodimeric
partner. To address the question of the effect of rexinoid antagonists on RAR/RXR function, we solved the crystal structure
of the heterodimer formed by the ligand binding domain (LBD) of the RARa bound to its natural agonist ligand (all-trans
retinoic acid, atRA) and RXRa bound to a rexinoid antagonist (LG100754). We observed that RARa exhibits the canonical
agonist conformation and RXRa an antagonist one with the C-terminal H12 flipping out to the solvent. Examination of the
protein-LG100754 interactions reveals that its propoxy group sterically prevents the H12 associating with the LBD, without
affecting the dimerization or the active conformation of RAR. Although LG100754 has been reported to act as a ‘phantom
ligand’ activating RAR in a cellular context, our structural data and biochemical assays demonstrate that LG100754 mediates
its effect as a full RXR antagonist. Finally we show that the ‘phantom ligand effect’ of the LG100754 is due to a direct
binding of the ligand to RAR that stabilizes coactivator interactions thus accounting for the observed transcriptional
activation of RAR/RXR.
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Introduction
Upon ligation to their cognate receptors, naturally-occurring
vitamin A derivates mediate several physiological processes, such
as vertebrate morphogenesis, cellular growth, differentiation or
survival, as well as pathological conditions e.g premature birth,
skin diseases or cancer development (reviewed in [1]). The atRA
isomer binds exclusively to RARs whereas the 9-cis form of RA
binds to both RARs and RXRs, (each of which exists as three
isoforms a, b and c) (reviewed in [2]).
The ability of RAR/RXR to modulate the expression of target
genes results from a combinatorial, coordinated and sequentially
orchestrated exchange between nuclear hormone receptors
(NHRs) and their coregulators. A general model of RAR/RXR-
mediated transcription proposes that unliganded RAR/RXR
heterodimers are bound to regulatory elements of their target
genes and interact with transcriptional repressor complexes such
as NCOR/SMRT/SIN3 to recruit histone deacetylases that lead
to repression of target gene transcription [3]. Binding of agonist
ligand to the nuclear receptor, triggers a conformational change in
the ligand binding domain (LBD) with the repositioning of the C-
terminal helix H12 creating a binding surface that allow
coactivator to bind. Coactivator proteins such as CBP/p300, the
p160 family, CARM1 or the Mediator contain one or more
consensus LXXLL motifs that form an a-helix that fits into the
hydrophobic cleft on the LBD to allow activation of target genes
[4]. Antagonist ligands that prevent the C-terminal helix H12
from adopting its active conformation facilitate the interactions
with corepressors.
A significant feature of RXR is its ability to act on its own or in
concert with other signalling pathways to induce cell differentia-
tion or apoptosis, as exemplified in immature human promyelo-
cytic NB4 cells [5]. RXR ligands (rexinoids)-mediated biological
outcomes depend on the nature and the liganded state of the
heterodimeric partner. As such, RAR/RXR is a non-permissive
heterodimer in which RAR agonists can autonomously activate
transcription while full responses to rexinoids occur only in the
presence of RAR agonist ligands [6–7]. In addition, RXR ligands
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ligand [8–9]. In sharp contrast, the permissive heterodimers
exemplified by PPAR/RXR or Nurr1/RXR are activated by
RXRs ligands per se [10,11].
For RAR/RXR heterodimers, the crystal structures of the fully
agonist and fully antagonist conformations havebeen reported [12–
13]. In the later one, the antagonist BMS614 bound to RARa
prevents the positioning of the active conformation of H12 that
occludes the coactivator binding site. We now report the crystal
structure of the heterodimer formed by the ligand binding domains
of the human RARa bound to an agonist (all-trans retinoic acid,
atRA) and the mouse RXRa bound to a rexinoid antagonist,
LG100754 (Figure 1) that has been shown to be an antagonist for
RXR homodimer and a selective heterodimer antagonist [14].
AlthoughLG100754activates the PPARa/RXR heterodimer[15],
it does not activate TR/RXR, VDR/RXR or LXR/RXR [14].
For RAR/RXR, it has been shown that the binding of LG100754
leads to transactivation mediatedby RAR [16]. Thiseffecthas been
termed the ‘‘phantom effect’’ and the proposed explanation is a
conformational change in RAR induced by the binding of
LG100754 to RXR promotes SRC-1 coactivator recruitment and
transactivation activation via RAR [14]. However a gene
expression activation study has shown that LG100754 acts as an
antagonist also for the RAR/RXR heterodimer [17]. LG100754
was also shown to be unable to release the corepressor SMRT from
RARin vitro[14],buttostimulate releaseofcorepressorsinanin vivo
study [16]. This discrepancy in the ability of LG100754 to promote
the dissociation of SMRT corepressor bound to RAR arises from a
difference in the sensitivity of the two assays that was closer to
physiological conditions in the in vivo study [16].
This new structure explains the RXR full antagonism activity of
LG100754. The comparison with the previous RAR/RXR
structures together with biochemical assays of the SRC-1
coactivator peptide recruitment to the heterodimer provides
insight into the molecular mechanism of LG100754 action and
explains its phantom effect.
Results and Discussion
Overall structure of the agonist/antagonist RARa/RXRa
LBD heterodimer
The crystal structure of the ternary molecular complex of
RARa-atRA/RXRa-LG100754 LBDs and TIF-2 coactivator
peptide was solved at 2.75 A ˚ resolution and contains the two
receptor LBDs bound to their respective ligands. One TIF-2
coactivator peptide is bound to RARa (Figure 2A). Both LBDs
adopt the canonical fold of NR LBDs and are bound to their
ligands as shown by the experimental 2Fo-Fc density map
(Figure 2B). The present structure adopts an asymmetric
agonist/antagonist conformation. Indeed, RARa bound to atRA
presents the active agonist conformation with the C-terminal helix
H12 sealing the ligand binding cavity and one coactivator peptide
bound through its LXXLL motif to the coactivator cleft generated
by H3, H4 and H12. On the other side, the RXRa LBD bound to
LG100754 adopts an antagonistic conformation with H12
pointing to the solvent and preventing the coactivator peptide
from binding to RXR. This antagonistic conformation of H12 is
different from that observed in the structure of the RXRa-oleic
acid in the fully antagonist RARa/RXRa heterodimer, where
H12 of RXRa in complex with oleic acid binds to its own cofactor
binding site [12]. In addition, we previously reported the crystal
structure of an asymmetric heterodimer of the complex of
ecdysone receptor (EcR) and ultraspiracle (USP), with EcR in an
active agonist conformation and USP in an antagonist one [18].
While in this latter structure, USP forms constitutively an
antagonistic conformation, with an inactive locked H12, in the
present one, the antagonist conformation is induced by the ligand.
Compared with the previous two RAR/RXR structures (PDB IDs
are 1DKF and 1XDK), the overall structures are similar to each
other except for H11 and H12. The root mean square deviation
(RMSD) between RARa-atRA/RXRa-LG100754 and the fully
agonists RARb/RXRa is 0.85 A ˚ over the Ca atoms (residues
185–415 for RARa, 178-408 for RARb and 231–248, 268–440
for RXRa). However, the present heterodimer arrangement shows
rigid body movement of RXRa LBD compared with the previous
heterodimers with a rotation by 3–4u from the C2 symmetry axis
of the dimer, although the overall structures of each RARs and
RXRs are similar to each other (Figure 3). The structure
superposition of the monomeric RAR and RXR LBDs onto their
corresponding heterodimers shows little variations between
monomeric and heterodimeric receptors with RMSDs of 0.55 A ˚
between the RARa-atRA and the RARb-9-cisRA, and 0.54 A ˚
between the RXRa-LG100754 and the RXRa-9-cisRA.
Solution structure determination of RARa-atRA/RXRa-
LG100754
The crystal packing induces an intermolecular interaction
between the flipped H12 of the RXRa-LG100754 and the
coactivator binding surface of a symmetry related RXR molecule
(Figure 4). This packing interface is made not only by the cofactor
binding site but also H11 of RAR, H6, LoopH6-H7, H7 and H11
of RXR (Figure 4). Total surface area buried between the packing
interface is 2000 A ˚ 2. Such tetrameric assembly induced by the
flipped H12 is also observed in the other crystal structures of RXR
[PDB IDs: 1LBD, 1G5Y, 1H9U, 2Q60, 2GL8] but the orientation
of the present tetramer is different from any other. The oligomeric
state of this complex in solution was determined by Small Angle
X-ray Scattering (SAXS) the values of the radius of gyration Rg
and of the maximal dimension Dmax as structural parameters
(Table 1 and Figure S1). We further compared them to those of
other RAR/RXR heterodimer or RXR homodimer or tetramer
[19] and to theoretical values calculated from crystallographic
structures. The values of Rg and of Dmax parameters measured for
the RARa-atRA/RXRa-LG100754 complex clearly indicate that
the complex is dimeric in solution. The Rg is 5 A ˚ smaller than that
calculated from the tetrameric crystal structure (Figure S1).
Furthermore, the best fit of the experimental data is obtained
unambiguously with the dimeric model in which one monomer is
in a closed conformation and the other one in an open
conformation with helix H12 pointing to the solvent (Figure S1).
The experimental Rg is 1 A ˚ larger than that of the heterodimer
fully bound to agonists indicating a less compact conformation and
1A ˚ smaller than the relaxed apo-form of RXR dimer (Table 1).
The tetramer generated by the crystallographic symmetry is
induced by the highly concentrated conditions during the
crystallization process.
Dimer interface analysis of the RARa-atRA/RXRa-
LG100754
The heterodimer interface is made by H7 (353–361), H9 (395–
410) and H10-H11 (417–435) of RXR, and LoopH8-H9 (336–
340), H9 (349–364), H10 (371–380) of RAR and is similar to those
of the previously solved RAR/RXR heterodimers. The compar-
ison of the heterodimer interface (Figure 3) between the present
asymmetric RARa/RXRa heterodimer, with the fully agonist
RARa/RXRa and the fully antagonist RARa/RXRa heterodi-
mers, using free energy decomposition analysis [20] showed that
The Rexinoid LG100754 in RAR/RXR Heterodimer
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The rigid body movement of RXRa LBD in the present RARa/
RXRa heterodimer caused a small reduction in the interface area,
but the salt bridges remained conserved (shown in Figure S2). The
intramolecular salt bridges which are specific to class I NHR LBDs
namely Glu244-Arg376 and Glu371-Arg419 for RXRa, and to
class II NHR LBDs, namely Asp267-Arg339 and Glu325-Arg367
for RAR are maintained [21]. The conformation and surrounding
network of Tyr402 of RXR which plays an important role for
dimerization [22] are also conserved.
Ligand binding mode in RARa-atRA/RXRa-LG100754
The binding mode of atRA (Figure 2B) to RARa in the present
heterodimer is identical to that observed previously for RARa
Figure 1. Chemical structures of the RAR and RXR ligands used in this study.
doi:10.1371/journal.pone.0015119.g001
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volume of the ligand binding cavity is 418 and 503 A ˚ 3 and the
retinoic acid occupies 66.5% and 55.3% of the pockets for RARa
and RARa, respectively. The difference of the cavity size around
100 A ˚ 3 is due to the different residues of the two isotypes forming
the ligand binding pocket (LBP).
The rexinoid antagonist LG100754 is buried in the LBP of
RXRa formed by residues located on helices 3, 5, 7, 11 and the b-
turn (Figure 5). The interactions are mainly hydrophobic with 80
Van Der Waals (VDW) contacts with the LBP at 4.2 A ˚ cutoff. The
carboxylate group makes an anchoring salt bridge with Arg321
[hArg316] (H5) and hydrogen bond with amino group of Ala332
[hAla327] (LoopH5-H6) in the hydrophobic pocket, similarly as
observed with the carboxylate of 9-cisRA in the RXRa complex
[24]. One water molecule makes a hydrogen bond network
between the carboxyl group of LG100754 and the amino group of
Leu314 [hLeu309]. The tetrahydronaphatalene moiety of
LG100754 interacts with residues of H3, H5, H7 and H11
through VDW contacts and notably with Trp310 [hTrp305] (H5)
(Figure 5). Compared to the 9-cisRA-bound RXR, the carboxylate
and tetrahydronaphatalene group of LG100754 are located at the
places which correspond to that of the carboxylate and b-ionone
group of 9-cisRA. The propoxy group is pointing towards H11 and
interacts with this helix through VDW contacts notably with
Leu441 [hLeu436] which is repositioned (Figure 6A). The electron
density map of the end of the propoxy group is poor because of its
flexibility (see Figure 2B). A remarkable feature is the solvent
accessibility of this LBP because of the flip of H12 to the solvent.
According to crystallographic symmetry, this accessible region of
the LBP is covered by LoopH11-H12 (mainly Phe443 [hPhe338]
and Asp449 [hAsp444]) of another RXRa symmetry related
molecule (Figure 4). The active agonistic conformation of H12 of
RXRa is prevented by the long-tailed propoxy group of
LG100754 which induces a steric hindrance with Leu456
[hLeu451], and consequently the coactivator peptide binding as
shown for the superimposition of RXR-LG100754 and RXR-9cis
RA (Figure 6A). Oleic acid, a neutral RXR ligand, has been
crystallized in an RXR agonist conformation in RXR homodimer
[25] and in an RXR antagonist conformation in RAR/RXR
heterodimer [12]. Superposition of RXRa bound to LG100754
and to oleic acid in RXR antagonist conformation shows two
different antagonist conformations. Indeed, the propoxy group of
LG100754 induces a steric hindrance with Leu446 [hLeu441] in
the LoopH11-H12 as observed in the RXR-oleic acid antagonist
conformation, precluding H12 binding to the coactivator cleft
(Figure 6B). This new structural information is in agreement with
the inability of RXRa-LG100754 homodimer to bind to any
coactivator or corepressor [26]. Phe442 [hPhe437] and Phe443
[hPhe438] in H11 of RXRa which are known to play important
roles in the transition of the apo to agonist conformation [13], flip
out to the solvent region in the present antagonistic structure
(Figure 6).
Structural comparison of LG100754 with other RXR
antagonists
Among the few reported RXR antagonists [27–28], two other
types have been described, namely the dibenzodiazepine deriva-
tive HX531 [29] and UVI3003 [30] (Figure 1). In the first case, a
docking model proposed [24] that the additional bulky NO2 group
of HX531 causes a steric hindrance with Gln311 [hGln306] (H5),
Trp310 [hTrp305] (H5) and Leu438 [hLeu433] (H10). Indeed, a
different antagonistic structure should result in different action on
coregulator interaction and function of RXR. Since Leu438
[hLeu433] is part of the dimerization interface, the steric
hindrance with Leu438 [hLeu433] is likely to affect the
dimerization.
In contrast, the structural basis of the antagonism of UVI3003
should be similar to that of LG100754. The crystal structure of the
complex of RXR and the partial agonist UVI3002 [30] (Figure 1)
reveals that the alkyl ether group of UVI3002 is located at the
same position as the propoxy group of LG100754 but its length do
not prevent the agonist conformation. Therefore, UVI3003 which
has a longer alkyl group than UVI3002 should similarly prevent
H12 associating to the LBD and the RXR complex should adopt
an antagonistic conformation as in RXR-LG100754. In agree-
ment with this molecular mechanism of antagonism, analogues of
LG100754 with shorter groups such as ethyl or methyl groups
Figure 2. Overall structures of the RARa-atRA/RXRa-LG100754
LBD heterodimer. (A)The RARa (in green)/RXRa (in cyan) heterodimer
is shown by the cylindrical helices representation. Helices are numbered
from N- to C-terminus with the activation helices H12 in red. The TIF-2
coactivator peptide bound to RARa through a surface formed by H3, H4
and H12 is shown in orange. The two ligands are shown by stick
representation with carbon and oxygen atoms colored in yellow and
red, respectively. (B) Conformations of the bound ligands. atRA
(left) and LG100754 (right) are shown in their 2Fo – Fc electron density
map contoured at 1.0 s.
doi:10.1371/journal.pone.0015119.g002
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agonist for RXR, respectively [31].
A recent NMR study on the effect of RXR antagonists on the
conformation of H12 in the RXR homodimer and in the
permissive PPAR/RXR with PPAR bound to an agonist ligand
reveals similar features, namely the rexinoid antagonist is unable
to stabilize a compact state and therefore prevents the coactivator
from binding to RXR [32].
LG100754 has no effect on the cross-talk between LBD
partners of RAR/RXR
As LG100754 triggers no effect on RAR structure within the
heterodimer, we decided to characterize the ligand effect on the
cross-talk between the LBD partners by monitoring the binding of
fluorescently labelled SRC-1 NR2 peptide to the heterodimer
using fluorescence anisotropy (Figure 7 and Table 2). In its apo-
form, the heterodimer was found to bind the SRC-1 NR2 peptide
with a 1:1 stoichiometry and a kd value in agreement with the
literature [13]. The binding of LG100754 in a concentration
sufficient to saturate only one site and in absence of RAR ligand
modifies neither the binding stoichiometry nor the heterodimer
affinity for the SRC-1 NR2 peptide (Table 2), in variance with the
‘‘phantom ligand effect’’ hypothesis, where the binding of
LG100754 to RXR was thought to affect the cofactor recruitment
by its apo-partner [16]. Finally, we repeated the titration in the
presence of both LG100754 and BMS614, a specific RARa
antagonist [9]. In this condition, the heterodimer binds to the
SRC-1 NR2 peptide with a strongly reduced affinity (kd.10 mM),
confirming that RARa LBD is the main binding site for the SRC-
1 NR2 peptide [13]. Taken together, these data show that
antagonists bound to RXRa do not affect the binding of the SRC-
1 NR2 peptide to the RARa apo-form.
In contrast, a significant increase in the binding constant
(kd=0.4260.03 mM) of the SRC-1 NR2 peptide for the
heterodimer was observed in the presence of the rexinoid agonist
BMS649 [33] (Figure 1). Moreover, an identical binding curve
(kd=0.4560.04 mM) was observed when the titration was
performed in the presence of both BMS614 and BMS649
(Figure 7). To check whether a ligand-induced structural change
on RARa affects the RXR ability to bind the coactivator peptide,
a titration of the labelled SRC-1NR2 peptide by the heterodimer
was performed in the presence of the RARa agonist AM580 [34]
(Figure 1), with or without LG100754 (Table 2). As expected,
AM580 alone enhances the heterodimer affinity for the SRC-1
NR2 peptide (kd=0.1960.02 mM), while in conjunction with
LG100754 similar results in terms of stoichiometry and binding
affinity were seen (kd=0.1760.01 mM) (Figure 7), confirming
that AM580 promotes the binding of the SRC-1 NR2 peptide to
the RARa subunit. The results above clearly show that ligand
binding to one subunit of the heterodimer does not positively
affect the SRC-1 peptide recruitment by the second subunit,
when in its apo-form. Moreover the binding of an antagonist
ligand to one subunit does not affect the recruitment of the
coactivator peptide on the other one. Binding experiment in the
presence of the two agonists ligands AM580 and BMS649 or 9-
cisRA (Figure 7 and Table 2) indicate a stoechiometry of 2
peptides bound to the heterodimer and that both RARa and
RXRa were able to bind the SRC-1 NR2 peptide with almost the
same affinity.
Direct binding to RARa can explain the phantom effect
of LG100754
To assess whether LG100754 is able to directly bind to RAR,
we monitored its interaction with RARa and RARa/RXRa LBD
Figure 3. Structural comparison of the RARa-atRA/RXRa-LG100754 LBD heterodimer with the fully agonists RARb-9-cisRA/RXRa-9-
cisRA heterodimer (PDB ID: 1XDK) showing a rigid body movement of RXR. The RARs are superimposed. The same color code as previously
is used while the fully agonists heterodimer is shown in red.
doi:10.1371/journal.pone.0015119.g003
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fivefold molar excess of LG100754 in the RARa LBD resulted
in the appearance of a novel series of mass/charge (m/z) ions
corresponding to a fully bound RARa-LG100754 complex
(Figure 8A). A molecular mass of 30380.462.5 Da was obtained
which corresponds to the binding of one molecule of LG100754 to
the RARa monomer (DM=396 Da). In the RAR/RXR dimer,
we mainly observed 2 molecules of ligand bound to the dimer
(DM=798 Da) (Figure 8B). In order to detect the protein/ligand
complexes, the capillary voltage (CE) which controls the kinetic
energy transferred to the ions in the interface region of the mass
spectrometer has to be carefully set. Below CE=80 V, protein/
ligand complexes are quantitatively formed; however, the
observed peak shapes are broad which probably results from
incomplete desolvation. A direct consequence of this is a poor
signal/noise ratio and a loss in mass accuracy. Increasing CE to
80 V significantly improves the signal/noise ratio and still allows
the detection of the protein/LG100754 complexes as the main
component. In contrast to the low binding affinity reported for the
binding of LG100754 to RARa [14], we show that this ligand
binds to RAR with a significant affinity. The discrepancy can be
explained by the low sensitivity of the methods used previously
[14]. The use of larger SRC-1 domain as reported [14] instead of
short peptide does not explain this discrepancy, as the SRC-1
domain (940-1061 [14]) used didn’t contain the nuclear receptor
interacting domain (SRC-1 RID 627–786 [35]). We then
monitored the effect of the LG100754 on the recruitment of the
SRC-1 NR2 coactivator peptide to RARa and RARa/RXRa.I n
absence of ligand, only a small proportion of RARa is able to bind
the SRC-1 NR2 peptide (Figure 8C top). The addition of
LG100754 strongly stabilizes the interactions between the RARa
monomer and the SRC-1 NR2 peptide since the RARa-
LG100754/SRC-1 NR2 complex is now the main species
(100%). As described previously for Figures 8A and 8B, decreasing
the CE voltage from 150 V to 80 V allows the detection of the
intact ternary complex. Interactions involving the ligand are thus
less stable than those involving the coactivator peptide in the gas
phase. Increasing the CE voltage to 200 V (data not shown) does
not lead to any major change in the dissociation pattern regarding
the complexes which suggest that the RARa/SRC-1 NR2
complex is quite stable in the gas phase. Note that we have not
observed SRC-1 coactivator peptide binding to RXRa-LG100754
(data not shown).
To quantify the recruitment of the SRC-1 NR2 peptide to
RARa, RXRa and RARa/RXRa, Isothermal Titration Calo-
rimetry (ITC) was used, thus providing the full thermodynamic
profile of SRC-1 binding. The similar SRC-1 NR2 peptide (25
residues) to the one used in ESI-MS was used in the ITC
experiments. Representative titrations for SRC-1 NR2 binding are
shown in Figure S3. In the presence of LG100754, the RARa
monomer binds the SRC-1 NR2 peptide with an affinity similar to
that measured in presence of an RAR agonist ligand (Figure 9 and
Table S2). Therefore, the LG100754 ligand stabilizes the agonist
conformation of RAR that renders accessible the binding surface
for coactivator recruitment. Docking of L100754 in the ligand
binding pocket of hRARa reveals that the ligand easily adapts to
fit the RARa agonist conformation without significant steric
clashes (Figure S4). No significant interaction of the SRC-1 NR2
peptide with RXRa LBD was observed (Figure S3) in agreement
with our ESI-MS data and with the literature [26]. In RAR/RXR
LBDs bound to LG100754, SRC-1 NR2 binds to the heterodimer
with a stoechiometry of one peptide per heterodimer and with an
affinity similar to the one for the RARa monomer. Together these
data demonstrate (Figure 9) that the LG100754 compound is able
to stabilize an agonist conformation when bound to RAR while in
RXR it inhibits the interaction with the coactivator SRC-1
peptide. LG100754 has also been shown to be able to dissociate
corepressors from RAR [16] and to prevent their binding to RXR
[26].
Figure 4. Crystal packing of the agonist/antagonist RAR/RXR
LBD heterodimer according to the crystallographic 2-fold
symmetry. The same color code as previously was used. The
crystallographic 2-fold symmetry related heterodimer is shown in gray.
Helices which are involved in the packing are labelled.
doi:10.1371/journal.pone.0015119.g004
Table 1. Small angle X-ray parameters.
Complexes Rg (A ˚)D max (A ˚)R gtheo(A ˚) x
RAR-9-cisRA/RXR-9-cisRA 26.060.2 8765
RAR-atRA/RXR-LG100754 27.260.2 9065
RXR/RXR-9-cisRA [19] 26.760.3 8065
apo RXR/RXR [19] 28.060.3 9265
apoRXR/RXR tetramer [19] 32.860.3 9565
RAR-atRA/RXR-LG100754 dimer 26.4 1.8
RAR-atRA/RXR-LG100754 tetramer 32.1 8.9
RXR/RAR-9-cisRA (1XDK) 26.0 2.6
RAR-BMS614/RXR-oleic acid
(1DKF)
26.1 2.5
Rg and Dmax are the radius of gyration and maximum size, respectively
computed from the entire scattering pattern using the indirect transform
package GNOM [56]. Rgtheo is the radius of gyration calculated from the crystal
structure using CRYSOL [57]. Discrepancy between the experimental data and
the scattering curves calculated from the crystal structures is denoted as x.
doi:10.1371/journal.pone.0015119.t001
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The crystal structure of the RAR-atRA/RXR-LG100754
complex revealed that RAR adopts an agonist conformation and
RXR an antagonist one. The RXR antagonist LG100754
conformation affects neither the dimerization of RAR/RXR nor
the active conformation of RAR. The orientation of the propoxy
group of LG100754 prevents H12 to packing against the LBD and
the coactivator peptide binding to RXR. A similar antagonist
mechanism has been observed in the crystal structure of the ERa
LBD bound to the anti-estrogen ICI164384 [36]. We observe that
LG100754 induces a high mobility of H12 and acts as a full RXR
antagonist. Fluorescence anisotropy titrations showed that the
presence of both agonists in the dimer leads to the highest affinity
for the coactivator peptide, the binding of an antagonist to one
subunit and of LG100754 to RXR does not affect the recruitment
of the coactivator by its partner. Our study gives an explanation to
the phantom effect of LG100754 that is due to its direct activation
through RAR. Our findings provide new insights into the wide
spectrum of molecular interactions in the RAR/RXR dimer and
for the design of more specific RXR antagonist drugs that have
great promise for the prevention and treatment of cancer and
metabolic diseases [37].
Materials and Methods
Materials and chemicals
LG100754 was kindly provided by MSD (N.V. Organon). 9-cis
retinoic acid (9-cisRA), atRA and AM580, a synthetic RAR pan-
agonist, were purchased from Sigma. BMS614 and BMS649 were
provided by Bristol-Myers Squibb. Fluorescent NR box2 motif
Figure 5. A stereoview of the interactions of LG100754 with the ligand binding pocket of RXRa. Only residues closer than 4.2 A ˚ to the
ligand are shown. Hydrogen bonds are shown as dotted lines. The secondary structure of the hRXRa-LBD and specific residues are labelled.
doi:10.1371/journal.pone.0015119.g005
Figure 6. Structural basis of RXR antagonism induced by LG100754. (A) Close-up view showing the superposition of RXRa LBP bound to
LG100754 (in cyan) and to 9-cisRA (in red). LG100754 and 9-cisRA are shown by stick representation in yellow and magenta, respectively, with oxygen
atoms in red. The propoxy group of LG100754 induces a steric hindrance (solid arrow) with Leu456 (H12). Residues involved in the transition agonist
to antagonist transition (dotted arrow) conformation are labelled. (B) Close up view of the superposition of RXRa LBP bound to LG100754 (in cyan)
and to oleic acid in antagonist conformation (in orange). Oleic acid is show by stick representation in magenta. The propoxy group of LG100754
induces a steric hindrance (solid arrow) with Leu446 as shown by an arrow.
doi:10.1371/journal.pone.0015119.g006
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peptide (SRC-1 NR2) was purchased from Neosystem (Strasbourg,
France).
Expression, Purification and Crystallization
The human RARa LBD (residues 153–421) was cloned as an
N-terminal hexahistidine-tagged fusion protein in a pET15b
expression vector and the mouse RXRa LBD (residues 228–467)
was cloned into a pET3a expression vector. Both were produced
in an E. coli BL21 (DE3) strain. Cells were grown in LB medium
for 3 h at 37uC and subsequently induced for 3 h at 20uC with
1 mM isopropyl-b-D-thiogalactopyranoside. The His-RAR/RXR
heterodimer was copurified by nickel affinity chromatography and
gel filtration. The final protein buffer was Tris-HCl 20 mM (pH
8.0), NaCl 150 mM, DTT 10 mM, and TCEP 2 mM. The
protein was concentrated to 3 mg/ml and incubated with a 1.5-
fold excess of atRA, LG100754 and the TIF-2 coactivator peptide
(686-KHKILHRLLQDSS-698) prior to crystallization assays.
Purity and homogeneity were assessed by SDS and Native PAGE
as well as denaturating and native electrospray ionization mass
spectrometry. Crystals of the ternary complexes of hRARa/
mRXRa LBDs and TIF-2 peptide were obtained at 17uCb y
vapor diffusion in hanging drops by mixing of 0.5 ml of the protein
solution and 0.5 ml of reservoir solution which contains 200 mM
potassium thiocyanate and 20% PEG3350.
Data Collection, Structure Determination and Refinement
The crystals were mounted in fiber loops and flash-cooled in
liquid nitrogen after cryoprotection with the reservoir solution plus
5% ethylene glycol. Of 100 crystals tested, only one diffracted to
2.75 A ˚. Data collection from the frozen crystal was performed at
100 K on the beamline ID23-1 at the ESRF (Grenoble, France).
The crystal belongs to the tetragonal space group P43212, with one
heterodimer per asymmetric unit. The data were integrated and
Figure 7. Titration of the TAMRA-labeled SRC-1 NR2 peptide with RARa/RXRa LBD bound with retinoid agonists or antagonists, as
monitored by fluorescence anisotropy. (A) Titration with the apo-heterodimer (&) or with the heterodimer bound to LG100754 (%), HX531 (N)
or a BMS614/LG100754 combination (#). (B) Titration with the heterodimer bound to BMS649 (&) or a BMS614/BMS649 combination (#). (C)
Titration with the heterodimer bound to AM580 (#) or AM580/LG100754 combination (&). (D) Titration with the heterodimer bound to 9-cisRA (#)
or a AM580/BMS649 combination (&). The concentration of TAMRA-labeled SRC-1 NR2 peptide is 1 mM for experiments reported in (B–D).
doi:10.1371/journal.pone.0015119.g007
Table 2. Binding constants of the SRC-1 NR2 peptide to the
RARa/RXRa LBD heterodimer.
RAR ligands RXR ligands n kd (mM)
apo apo 1 260.1; 360.6
c
apo LG100754 1 2.560.1
apo BMS649 1 0.4260.03
AM580 apo 1 0.1960.02
AM580 LG100754 1 0.1760.01
BMS614 BMS649 1 0.4560.04
BMS614 LG100754 1
a .10
a
9-cisRA 9-cisRA 2 (0.6160.02)
b
AM580 BMS649 2 (0.2960.02)
b
Experiments were carried out by fluorescence anisotropy using the TAMRA-
labeled SRC-1 NR2 peptide in a 10 mM TRIS-HCl (pH 7.5), 150 mM NaCl, 10 mM
DTT.
aThe binding stoichiometry could not be determined in this case, due to the too
low affinity.
bFitting the experimental points systematically provided a k2 value identical to
that of k1, indicating that the two dissociation constants are very close to each
other.
cfrom reference [13].
doi:10.1371/journal.pone.0015119.t002
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was solved by molecular replacement using the program AMoRe
[39]. The structure of the antagonist-bound heterodimer (PDB ID:
1DKF) was used as a starting model. Refinement involved iterative
cycles of manual building and refinement calculations. The
programs CNS [40], REFMAC [41], phenix.refine [42], O [43]
and COOT [44] were used throughout structure determination
and refinement. Several terminal residues and 13 residues between
H1 and H3 of RXR (251-263) are not modelled as the electron
density map was poor in the corresponding regions. The TIF-2
peptide and the ligand molecules were only included at the last
stage of the refinement. The omit map from the refined atomic
model of the heterodimer was used to fit the peptide and ligands to
their electron densities (Figure S5). Anisotropic scaling, a bulk
solvent correction and TLS restraints were used for the
refinement. Seven TLS groups for each LBD and one group for
the peptide were generated by using the program TLSMD [45].
Individual atomic B factors were refined isotropically. Solvent
molecules were then placed according to unassigned peaks in the
electron density map. In the RARa-atRA/RXRa-LG100754
LBDs and TIF-2 peptide complex, refined at 2.75 A ˚ with no s
cutoff, the final model contains 239 residues (177–415) for hRARa
LBD, 218 residues (230–250, 265–461) for mRXRa LBD, 11
residues for TIF-2 peptide, 2 ligand molecules, and 115 water
molecules. According to PROCHECK [46], 91.5% of the peptide
lies in the core regions, 8.2% in the allowed regions and 0.2% in
the generous region. The peptide classified in the generous region
of the Ramachandran plot is around Asp449 of RXR. Since this
peptide is located at the loop between H11 and H12, such
unfavourable conformation is adapted due to intermolecular
interaction imposed on H12 by crystal packing (described below).
Data are summarized in Table S1. The volumes of the ligand-
binding pockets and ligands were calculated by using the program
VOIDOO [47] and GRASP [48], respectively. Structural figures
were generated by using the Pymol program [49] and CCP4MG
[50].
Free energy decomposition
To quantify the electrostatic and van der Waals contributions to
dimer association, a free energy decomposition analysis was
Figure 8. LG100754 binds to both RAR and RXR. (A) Enlarged view of the 11+ and 12+ ions of the ESI mass spectrum of RARa in absence (top)
and in presence (down) of fivefold molar excess of LG100754 (CE=80 V). Additional peaks at +60 Da (a) might correspond to acetate adducts. (B) ESI
mass spectrum of the RARa/RXRa heterodimer in absence (top) and in presence of fivefold molar excess of LG100754 (CE=80 V) (C) Influence of the
LG100754 ligand binding on the recruitement of the SRC-1 NR2 peptide by RARa.
doi:10.1371/journal.pone.0015119.g008
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and fully antagonists conformations [12–13]. Starting from the
crystal structures hydrogen atoms were added using the HBUILD
[51] module of the CHARMM (Chemistry at HARvard
Macromolecular Mechanics) program [52]. The structures were
energy minimized and subsequently used in a MM/PBSA
decomposition protocol. Details of the protocol are described in
reference [20]. Docking of the ligand LG100754 in the binding
pocket of hRARa LBD in agonist conformation was performed
with Autodock 4.0 using standard input parameters.
SAXS experiments and data processing
The synchrotron radiation X-ray scattering data were collected
at the storage ring DORIS III of the Deutsches Elektronen
Synchrotron (DESY) [53]. The scattering patterns were recorded
in the range of momentum transfer 0.15,s,3.5 nm-
(s=4psin(h)/l where 2h is the scattering angle and l=0.15 nm
is the X-ray wavelength). All studied complexes were measured for
at least three protein concentrations ranging from 2 to 5 mg/ml.
To check for radiation damage, the data were collected in 1-
minute frames which were averaged and processed using standard
procedures by PRIMUS [54]. The forward scattering I(0) and the
radii of gyration Rg were evaluated using the Guinier approxi-
mation [55] assuming that at very small angles (s,1.3/Rg) the
intensity is represented as I(s)=I(0)exp{-(sRg)2/3}. These param-
eters were also computed from the entire scattering pattern using
the indirect transform package GNOM [56], which also provides
the maximum dimension of the particle Dmax and the distance
distribution function P(r). Theoretical values from crystal struc-
tures were calculated with CRYSOL [57].
Fluorescence anisotropy measurements
Steady-state fluorescence anisotropy measurements were per-
formed with a T-format SLM 8000 spectrofluorometer, thermo-
stated at 20uC. A home-built device ensured the automatic
rotation of the excitation polarizer. Anisotropy titrations were
carried out by adding increasing hRARa/mRXRa LBDs
concentrations to a fixed concentration of tetramethylrhodamine
(TAMRA) – SRC-1 NR2 peptide in 10 mM TRIS-HCl (pH 7.5),
150 mM NaCl, 10 mM DTT buffer. The binding stoichiometry
was determined at peptide concentrations between 1 mM and
10 mM, while the binding constants were determined at a peptide
concentration of 1 mM. The excitation wavelength was 530 nm
and the emitted light was monitored through high-pass filters
(550 nm, Kodak). The Scatchard equation was rewritten to fit the
anisotropy, r, as follows:
r~r0z rf{r0
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where Pt and St, designate the total concentration of the
heterodimer and (TAMRA) – SRC-1 peptide, respectively. rf
represents the anisotropy at the plateau when all the heterodimer
is bound, whereas r0 and r correspond to the anisotropy values of
(TAMRA) – SRC-1 NR2 in the absence and in the presence of a
given concentration of heterodimer, respectively. kd and n
correspond to the apparent dissociation constant and the number
of binding sites for SRC-1 binding to the heterodimer,
respectively. The titration curves were fitted with the Microcal
Origin 6.1 software based on the nonlinear, least-squares method
and the Levenberg– Marquardt algorithm.
Electrospray ionization mass spectrometry
Prior to ESI-MS analysis, samples were desalted on Zeba Spin
desalting column (Pierce) in 200 mM ammonium acetate (pH 8.0).
ESI-MS measurements were performed on an electrospray
time-of-flight mass spectrometer (MicrOTOF, Bruker Daltonic,
Figure 9. Summary of the effects of ligands on the affinity and stoechiometry of SRC-1 NR2 peptide measured by ITC.
a dissociation
constants measured by fluorescence anisotropy.
b from reference [13]. N.D. not determined.
doi:10.1371/journal.pone.0015119.g009
The Rexinoid LG100754 in RAR/RXR Heterodimer
PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e15119Germany). Purity and homogeneity of the retinoid receptors were
verified by mass spectrometry analysis in denaturing conditions:
proteins were diluted to 5 pmol/ml in a 1:1 water-acetonitrile
mixture (v/v) acidified with 1% formic acid. Mass spectra were
recorded in the positive ion mode after calibration with horse
heart myoglobin diluted to 2 pmol/ml in a 1:1 water-acetonitrile
mixture (v/v) acidified with 1% formic acid. The following
molecular weights were measured: 29983.661.6 Da for RARa
and 30159.962.2 Da corresponding to an additional covalent
modification of the His-tag (gluconoylation). A molecular mass of
26734.461.8 Da was obtained for RXRa. These results were in
agreement with the molecular weights calculated from the known
amino acid sequences.
The mass measurements of the noncovalent complexes were
performed in ammonium acetate (200 mM; pH 8.0). Samples
were diluted to 10 pmol/ml in the previous buffer and continu-
ously infused into the ESI ion source at a flow rate of 3 ml/min
through a Harvard syringe pump (Harvard Apparatus model 11).
When studying non covalent complexes, a careful tuning of the
parameters is necessary to transfer intact supramolecular com-
plexes from the solution to the gas phase [58]. Attention must be
specially paid to parameters related to the interface of the mass
spectrometer. In particular, the hexapole RF value was set to
320 V and the capillary exit voltage (CE) was adjusted in each
case. For the interaction analysis, ligands and SRC-1 NR2 peptide
(676-CPSSHSSLTERHKILHRLLQEGSPS-700) were added to
the proteins in a 5 fold molar excess.
Isothermal titration calorimetry (ITC)
ITC measurements were performed at 30uCo naM i c r o C a l
ITC200 (MicroCal). Purified proteins were dialyzed extensively against
the buffer used in the ITC experiments. The buffer contained 20 mM
Tris pH 8.0, 200 mM sodium chloride. In a typical experiment, 1.5
or 2 ml aliquots of SRC-1 NR2 peptide (676-CPSSHSSLTERH-
KILHRLLQEGSPS-700) at 1.3 mM were injected at 0.5 ml.s
21 into
a2 0 - 5 0mM RAR, RXR or RAR/RXR complexes solution (200 ml
sample cell). In the complexes with ligands, ligand concentrations are
in fivefold molar excess of NHR in all titrations. Equivalent amounts
of ligand are added to both protein and peptide solutions and the
ethanol concentrations are adjusted to 2% for all titrations. The delay
between injections was 120 to 180 s to permit the signal to return to
baseline before the next injection. ITC titration curves were analyzed
using the software Origin 7.0 (OriginLab). Standard free energies of
binding and entropic contributions were obtained, respectively, as
DG=2RT ln(Ka)a n dTDS=DH 2 DG,f r o mt h eKa and DH values
derived from ITC curve fitting.
Protein Data Bank Accession Number
The accession number for the coordinates of the complex
reported in this article is 3A9E.
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Figure S1 RARa-atRA/RXRa-LG100754 LBDs is dimer-
ic in solution. (A) Comparison of the experimental SAXS curve
of atRA-RAR/LG100754-RXR (blue cross) with the correspond-
ing fits for the crystallographic model of the dimer (pink line), the
tetramer (yellow line) and of the full-agonists dimer (cyan line). (B)
Electron pair distribution [P(r)] function computed from the
experimental SAXS data.
(EPS)
Figure S2 Salt bridges at the heterodimer interface
between RARa-atRA LBD and the RXRa-LG100754 LBD.
The RXR and RAR are shown by cartoon representation in green
and cyan, respectively. Only residues forming salt bridges (dotted
lines) are shown with oxygen atoms in red and nitrogen atoms in
blue.
(EPS)
Figure S3 Representative ITC titrations of SRC-1 NR2
peptide into RAR and RAR/RXR.
(EPS)
Figure S4 Docked complex between hRARa in agonist
conformation and ligand LG100754 (in yellow). Retinoic
acid (in green) experimental position is indicated for comparison.
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Figure S5 Fo – Fc electron density omit map contoured
at 3.0 s for LG100754 (left) and atRA (right).
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